NO2385948T3 - - Google Patents

Info

Publication number
NO2385948T3
NO2385948T3 NO10760108A NO10760108A NO2385948T3 NO 2385948 T3 NO2385948 T3 NO 2385948T3 NO 10760108 A NO10760108 A NO 10760108A NO 10760108 A NO10760108 A NO 10760108A NO 2385948 T3 NO2385948 T3 NO 2385948T3
Authority
NO
Norway
Application number
NO10760108A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2385948T3 publication Critical patent/NO2385948T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO10760108A 2009-10-13 2010-08-31 NO2385948T3 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1249KO2009 2009-10-13
PCT/IN2010/000579 WO2011045811A1 (en) 2009-10-13 2010-08-31 Fused thiazolo and oxazolo pyrimidinones

Publications (1)

Publication Number Publication Date
NO2385948T3 true NO2385948T3 (pt) 2018-03-03

Family

ID=43034589

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10760108A NO2385948T3 (pt) 2009-10-13 2010-08-31

Country Status (27)

Country Link
EP (1) EP2385948B1 (pt)
JP (1) JP5681195B2 (pt)
KR (1) KR101710430B1 (pt)
CN (1) CN102549000B (pt)
AR (1) AR080616A1 (pt)
AU (1) AU2010307984B2 (pt)
BR (1) BR112012006233B8 (pt)
CA (1) CA2772995C (pt)
CY (1) CY1119710T1 (pt)
DK (1) DK2385948T3 (pt)
EA (1) EA020228B1 (pt)
ES (1) ES2653931T3 (pt)
HR (1) HRP20171976T1 (pt)
HU (1) HUE038051T2 (pt)
IL (1) IL219116A (pt)
LT (1) LT2385948T (pt)
MX (1) MX2012004074A (pt)
MY (1) MY157629A (pt)
NO (1) NO2385948T3 (pt)
NZ (1) NZ598020A (pt)
PL (1) PL2385948T3 (pt)
RS (1) RS56630B1 (pt)
SI (1) SI2385948T1 (pt)
TW (1) TWI500623B (pt)
UA (1) UA107473C2 (pt)
WO (1) WO2011045811A1 (pt)
ZA (1) ZA201203262B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI661828B (zh) 2013-05-14 2019-06-11 印度商托仁特生技有限公司 低劑量藥物組合物及其用途
ES2898476T3 (es) 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Compuesto de quinolona y uso del mismo
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途
CN110511233B (zh) * 2019-08-08 2022-01-25 成都大学 一种噻唑并[2,3-b]噁唑酮类化合物及其制备方法和用途
CN112778333B (zh) * 2021-01-23 2022-07-05 中国科学院新疆理化技术研究所 一种四氢噁唑并吡啶并氮氧杂酮类衍生物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072679A (en) * 1976-06-15 1978-02-07 E. R. Squibb & Sons, Inc. 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides
DK151811C (da) * 1979-11-23 1988-06-06 Pfizer Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-1-oxo-1h-thiazolooe3,2-aaa-pyrimidin-2-carboxamider eller farmaceutisk acceptable kationsalte deraf samt 1-oxo-1h-thiazolooe3,2-aaapyrimidin-2-carboxylsyrer til anvendelse som udgangsmaterialer ved fremgangsmaaden
US4423048A (en) 1979-11-23 1983-12-27 Pfizer Inc. Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor
JPH0539293A (ja) * 1991-01-23 1993-02-19 Kyowa Hakko Kogyo Co Ltd 免疫調節剤及びチアゾロピリミジン誘導体
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
CN1602360A (zh) 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
RU2333203C2 (ru) 2002-12-25 2008-09-10 Дайити Фармасьютикал Ко., Лтд. Диаминовые производные
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
WO2009039321A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039322A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Also Published As

Publication number Publication date
MY157629A (en) 2016-07-15
NZ598020A (en) 2013-11-29
AU2010307984B2 (en) 2013-11-07
JP5681195B2 (ja) 2015-03-04
ES2653931T3 (es) 2018-02-09
IL219116A0 (en) 2012-06-28
EA020228B1 (ru) 2014-09-30
UA107473C2 (uk) 2015-01-12
CN102549000B (zh) 2015-12-02
EP2385948A1 (en) 2011-11-16
BR112012006233A2 (pt) 2020-08-11
RS56630B1 (sr) 2018-03-30
TW201113290A (en) 2011-04-16
CY1119710T1 (el) 2018-06-27
EA201270556A1 (ru) 2013-01-30
CA2772995A1 (en) 2011-04-21
TWI500623B (zh) 2015-09-21
IL219116A (en) 2016-05-31
BR112012006233B1 (pt) 2021-05-18
CN102549000A (zh) 2012-07-04
LT2385948T (lt) 2018-01-10
MX2012004074A (es) 2012-05-22
DK2385948T3 (en) 2017-12-04
HUE038051T2 (hu) 2018-10-29
WO2011045811A1 (en) 2011-04-21
EP2385948B1 (en) 2017-10-04
KR101710430B1 (ko) 2017-02-27
BR112012006233B8 (pt) 2021-05-25
AU2010307984A1 (en) 2012-03-01
HRP20171976T1 (hr) 2018-02-09
PL2385948T3 (pl) 2018-02-28
CA2772995C (en) 2018-03-13
AR080616A1 (es) 2012-04-25
JP2013507435A (ja) 2013-03-04
ZA201203262B (en) 2013-01-30
SI2385948T1 (en) 2018-04-30
KR20120093907A (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
BE2015C040I2 (pt)
BR112012012396A2 (pt)
BR112012003062A2 (pt)
BR112012008195A2 (pt)
BR112012000607A2 (pt)
BRPI0925311A2 (pt)
BRPI0924307A2 (pt)
BR122021004633A2 (pt)
BR112012003080A2 (pt)
BR122017024704A2 (pt)
BR112012012487A2 (pt)
BR112012000665A2 (pt)
BR112012003853A2 (pt)
BR112012009797A2 (pt)
BR112012012080A2 (pt)
BR112012009446A2 (pt)
BR112012009703A2 (pt)
BR112012010357A2 (pt)
BR112012007656A2 (pt)
BR112012001263A2 (pt)
BR122019005883A2 (pt)
BR112012002627A2 (pt)
BR112012000159A2 (pt)
BRPI0924534A2 (pt)
BR112012014856A2 (pt)